Alejandro Hernández-Camba

Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study

María Chaparro, Ana Garre, Andrea Núñez Ortiz et al. · Journal of Clinical Medicine · 2021 · 92 citations · Full text

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Marc Ferrante, Geert D’Haens, Vipul Jairath et al. · The Lancet · 2024 · 76 citations

Moderately-to-severely Active Crohn, Immunology, Gastroenterology +5

Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study

María Chaparro, Iria Bastón‐Rey, E Fernández-Salgado et al. · Inflammatory Bowel Diseases · 2022 · 59 citations · Full text

Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry

Míriam Mañosa, A Fernández-Clotet, Pilar Nos et al. · Digestive and Liver Disease · 2022 · 42 citations

Eneida Registry, Gastroenterology, Clinical Gastroenterology +4

Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

María Chaparro, Diana Acosta, Cristina Rodríguez et al. · The American Journal of Gastroenterology · 2022 · 31 citations